The Integrated Forecasting and Analysis Tool   Login Now

Amylin Pharmaceuticals

EvaluatePharma® delivers unique insight into the past and future performance of companies in the pharmaceutical and biotechnology sector, in a user-friendly, online subscription service. A small selected sample of reports and related news headlines for Amylin Pharmaceuticals are available below. Free sample reports are also available for other Companies. To find out how you can access more detailed information on Amylin Pharmaceuticals, or on any other Company covered by EvaluatePharma® Contact Us today.

CONSENSUS FORECASTS ($US mln) -  Sales Forecasts available to EvaluatePharma Subscribers

Annual Sales WW - Sales Growth per Year (%)   Rank Product Generic Name Pharmacological Class 2006 2007 2007 Amylin Pharmaceuticals 1 Byetta exenatide Glucagon-like peptide 1 (GLP-1) agonist 430 636   48%     2 Symlin pramlintide acetate Amylin receptor agonist 44 66   50%       Note: Shaded Cells

PIPELINE ANALYSIS - Sales Forecasts available to EvaluatePharma Subscribers

Rank Product Therapeutic Category Therapeutic Subcategory Pharmacological Class Phase (Current) Amylin Pharmaceuticals 1 Byetta LAR Endocrine Anti-diabetics Glucagon-like peptide 1 (GLP-1) agonist Phase III   - AC162352 Gastro-Intestinal Anti-obesity agents Peptide YY (PYY) 3-36 Phase I   - Byetta (Nasal formulation) Endocrine Anti-diabetics Glucagon-like peptide 1 (GLP-1) agonist Phase I

FINANCIAL DATA ($US mln) - Forecasts available to EvaluatePharma Subscribers

Amylin Pharmaceuticals   2005 2006  Valuation Measures   Based on Latest Share Prices      Valuing the Equity        Market Capitalisation 3,802 3,802        PE Ratio (diluted) - Normalised (x) (14.2) (16.1)        Valuing the Enterprise        Enterprise Value 3,603 3,603        Free Cash Flow (Pre-Dividends) (205) (218)        FCF Yield (%) (5.7%) (6.1%)    Forecast Financials   Income Statement      Total Revenues 140 511      Cost of Goods Sold (15) (50)      S,G & A (172) (282)      R&D (132) (222)      Other Income/ Expense - Net (31) (194)      EBIT - Normalised (209) (237)      Net Interest & Financial Items 2 26      Pre-tax Profits - Normalised (207) (211)      Exceptionals - (8)      Income Before Taxes (207) (219)      Tax 0 0      Tax Rate (%) 0.0% 0.0%      Net Income - Reported (207) (219)      Net Income - Normalised (207) (211)     Per Share Data      EPS - Diluted (1.96) (1.78)      EPS - Basic (1.96) (1.78)      EPS - Normalised (diluted) (1.96) (1.72)      EPS - Normalised (basic) (1.96) (1.72)      Avg. Shares Outstanding - Diluted 105.5 122.6      Avg. Shares Outstanding - Basic 105.5 122.6      DPS 0.00 0.00

NEWS - Selected Product News Headlines (as of 11 June 2008)

ADA kicks off GLP-1 succession saga   (Amylin Pharmaceuticals)   10-Jun-2008 After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight   (Amylin Pharmaceuticals)   09-Jun-2008 After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight   (Eli Lilly)   09-Jun-2008 ADA - DPP-IVs and GLP-1s steal the show   (Merck & Co)   09-Jun-2008 Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin   (Amylin Pharmaceuticals)   09-Jun-2008 After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight   (Alkermes)   09-Jun-2008 Monotherapy BYETTA® (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss   (Eli Lilly)   07-Jun-2008 Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight   (Eli Lilly)   07-Jun-2008 Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight   (Alkermes)   07-Jun-2008 Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight   (Amylin Pharmaceuticals)   07-Jun-2008 Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss   (Amylin Pharmaceuticals)   07-Jun-2008 Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity   (Amylin Pharmaceuticals)   05-May-2008 SYMLIN Pen-Injector Devices Now Available   (Amylin Pharmaceuticals)   07-Jan-2008 Monotherapy BYETTA® Showed Significant Improvement in Glucose Control and Weight Loss in Adults with Type 2 Diabetes   (Eli Lilly)   06-Dec-2007 Monotherapy BYETTA(R) Showed Significant Improvement in Glucose Control and Weight Loss in Adults with Type 2 Diabetes   (Amylin Pharmaceuticals)   06-Dec-2007 Amylin Pharmaceuticals to Present at Research & Development Day   (Amylin Pharmaceuticals)   21-Nov-2007 Pramlintide and Leptin Combination Treatment Demonstrates 12.7 Percent Weight Loss in 24-Week Clinical Obesity Study   (Amylin Pharmaceuticals)   15-Nov-2007 Novo Nordisk should play Liraglutide time advantage   (Novo Nordisk)   01-Nov-2007 Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study   (Eli Lilly)   31-Oct-2007 FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use   (Amylin Pharmaceuticals)   01-Oct-2007 BYETTA® Study Showed Sustained Blood Glucose Control Over Three Years in People with Type 2 Diabetes   (Eli Lilly)   25-Jun-2007 BYETTA® Study Showed Comparable Blood Glucose Control to Insulin   (Eli Lilly)   24-Jun-2007 BYETTA® Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes   (Eli Lilly)   23-Jun-2007 SYMLIN(R) Used in Conjunction with Basal Insulin in Patients with Type 2 Diabetes   (Amylin Pharmaceuticals)   23-Jun-2007 Amylin Pharmaceuticals to Present New Data from Broad Diabetes and Obesity Programs at ADA 2007   (Amylin Pharmaceuticals)   19-Jun-2007

IN-DEPTH COMPETITIVE INTELLIGENCE AVAILABLE ON

Product Generic Name Amylin Pharmaceuticals 2nd Generation Amylinomimetic -   AC162352 -   AC2592 -   AC3056 -   Byetta exenatide   Byetta (Nasal formulation) exenatide   Byetta LAR exenatide   DynaCirc isradipine   DynaCirc CR isradipine   GIP agonists -   Humatrope somatropin   InnoPran XL propranolol   Leptin metreleptin   Lescol fluvastatin   Lescol XL fluvastatin   Pramlintide/Metreleptin metreleptin & pramlintide   Symlin pramlintide acetate

EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts for marketed and emerging products are built-up using recent research reports from top equity analysts. Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I, phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy, patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates, deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age - plus many more data items and analytics unique to EvaluatePharma®. Aggregations of these measures at a high-level means that companies may be ranked against each other on items such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs organic sales), sales by therapy area or technology and various other concentration measures. These aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis. Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.

Source: EvaluatePharma ®

Generated at 13:54:28 (GMT) on 11-Jun-2008

© 2008 EvaluatePharma Ltd